Abstract 417P
Background
Soft tissue sarcomas belong to a heterogeneous group of malignant tumours of mesenchymal origin which constitutes <1% of adult cancers and 12% of paediatric cancers. This study highlights the clinical spectrum of sarcomas, various histological patterns and survival outcomes. The intent is to study retrospectively the clinicopathologic profile and survival outcomes of soft tissue sarcomas and bone sarcomas treated with radiation therapy at a Regional Cancer Centre from South India.
Methods
The clinical and treatment details of patients were collected retrospectively for the period 2014 -2017 and were analysed using descriptive statistics. Survival analysis was done using Kaplan-Meir Analysis.
Results
The median age of presentation was 42 years (Range 2-80). Among the 123 patients studied , 54.5%(n = 67) were males and 45.5%(n = 56) were females. The most common presenting complaint was swelling 69% (n = 85) followed by pain 38.2% (n = 47). The most common site of involvement was extremity 48% (n = 59). Other more commonly involved sites were Genitourinary 7.3%(n = 9) and uterus 4.9% (n = 6). The most common histology was Ewing Sarcoma 14.6%(n = 18) followed by Undifferentiated Pleomorphic Sarcoma 13.8% (n = 17). Around 17.9%(n = 22) had metastatic disease at presentation, of which metastasis to lungs (n = 13) was most common, followed by bone (n = 8) and liver(n = 4). The intent of Radiation Therapy was Adjuvant 54.4%(n = 67), Palliative 32.2%(n = 21), Radical 13.8 (n = 17) and Neoadjuvant 6.5%(n = 8). Only 65.9%(n = 81) completed their intended radiation therapy. 91.9% (n = 113) received External Beam Radiation Therapy and 13% (n = 16) received Brachytherapy. Around 48.8% (n = 60) underwent surgery and 66.6% (n = 82) received some form of chemotherapy. The Mean Overall Survival was 50.4 months (95% CI 44.2-56.5 months). Median OS was not reached.
Conclusions
As per our study, the most common histology was Ewing Sarcoma, followed by Undifferentiated Pleomorphic sarcoma. Approximately 70% of sarcoma patients referred to Radiation Oncology department were for Curative intent whereas 30% with palliative intent and this has led to Mean OS of 50.4 months. At the same time with limited follow up data and the low number of events, the Median OS was not reached.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract